Innovator IBD 50 ETF Price & Performance (FFTY)

The Innovator IBD 50 ETF (FFTY) has delivered a 14.2% year-to-date return, far exceeding the S&P 500’s 5.8%. Financial giants American Express and Citigroup are key drivers, benefiting from strong earnings and operational improvements. The ETF’s focus on growth stocks with robust fundamentals is resonating amid ongoing economic uncertainty.12

Recent filings show FFTY’s portfolio now includes 52 positions, with new entries such as Rocket Lab, Robinhood, and Reddit. Top holdings feature Hims & Hers Health and Palantir. These changes reflect the ETF’s strategy of capturing emerging growth stories and adjusting to evolving market trends.31

Institutional investors have made notable moves in the Innovator IBD 50 ETF. LPL Financial reduced its position by nearly 15% last quarter, while others like Jane Street Group and Raymond James Financial increased their stakes. The ETF’s price remains volatile, trading between $22.91 and $34.26 over the past year.45